Printer Friendly Version

Send to a Friend

Bavarian Nordic A/S started vaccine production at its 9,000-square meter facility in Kvistgaard, Denmark, on July 4, 2005. Built by engineering and consultancy company NNE , construction on the 11-month fast-track project began on August 1, 2004. The facility can produce 40 to 60 million doses of Imvamune™ (the company’s MVA smallpox vaccine) annually. Housing cleanrooms that meet or exceed FDA and EU standards and are three times the size of industry norms, the facility features flexible disposal technology for ease of adjustment to the production of other vaccines.